SCHEMBL1198487

SCHEMBL1198487

C#Cc1cc(-c2csc(Cn3cc(C(=O)OCC)cn3)n2)cc(C(F)(F)F)c1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 8/20 0.39
L3MBTL1 Q9Y468 6/20 0.39
HPGD P15428 5/20 0.39
ALDH1A1 P00352 5/20 0.39
CYP1A2 P05177 2/20 0.39
CYP2C9 P11712 2/20 0.39
CYP2C19 P33261 2/20 0.39
MAPT P10636 7/20 0.38
MEN1 O00255 5/20 0.38
KMT2A Q03164 5/20 0.38
GAA P10253 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
GRM2 Q14416 1/20 0.37
GRM5 P41594 1/20 0.37
MAPK1 P28482 1/20 0.35
TP53 P04637 1/20 0.35
PPARD Q03181 1/20 0.34
ALK Q9UM73 2/20 0.34
HSP90AA1 P07900 1/20 0.33
CRHBP P24387 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198745 0.92 MAPK1 (0.42) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL1198899 0.91 KDM4E (0.44) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL1199251 0.90 KDM4E (0.38) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL12876283 0.89 GRM2 (0.38) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL12875727 0.89 KDM4E (0.44) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL1198941 0.88 KDM4E (0.47) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL1198158 0.88 L3MBTL1 (0.43) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL1198832 0.87 ALK (0.42) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL1198035 0.87 L3MBTL1 (0.41) KDM4EL3MBTL1HPGDALDH1A1CYP1A2
SCHEMBL1199085 0.87 KDM4E (0.41) KDM4EL3MBTL1HPGDALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A KDM4E 1877/4885L3MBTL1 4726/4885HPGD 74/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.